Sensitivity of rapid antigen tests for COVID-19 during the Omicron variant outbreak among players and staff members of the Japan Professional Football League and clubs: a retrospective observational study

BMJ Open. 2023 Jan 30;13(1):e067591. doi: 10.1136/bmjopen-2022-067591.

Abstract

Objectives: Rapid antigen tests have been used to prevent the spread of the COVID-19; however, there have been concerns about their decreased sensitivity to the Omicron variant. In this study, we assessed the sensitivity and specificity of the rapid antigen test compared with the PCR test among the players and staff members of the Japan Professional Football League and clubs. Furthermore, we evaluated the relationship between the sensitivity and the duration from the onset of symptoms to testing or vaccine status.

Design: This was a retrospective observational study.

Methods: We used 656 results from both the rapid antigen and PCR tests for COVID-19 using samples collected on the same day from 12 January to 2 March 2022, during the Omicron variant outbreak in Japan.

Results: The sensitivity of the rapid antigen test compared with the PCR test was 0.63 (95% CI: 0.53 to 0.73) and the specificity was 0.998 (95% CI: 0.995 to 1.000). There were no significant associations between the sensitivity and the duration from the onset of symptoms to testing (including asymptomatic cases in the category) or vaccination status (p>0.05) with small effect sizes (Cramer's V or φ: ≤0.22).

Conclusions: Even during the Omicron outbreak, the sensitivity of the rapid antigen tests did not depend on the duration from the onset of symptoms to testing.

Keywords: COVID-19; infection control; infectious diseases; risk management.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Athletes*
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology
  • COVID-19 Testing*
  • Disease Outbreaks / prevention & control
  • Football*
  • Humans
  • Japan / epidemiology
  • SARS-CoV-2 / genetics

Supplementary concepts

  • SARS-CoV-2 variants